Alpha1-antitrypsin deficiency - A model for conformational diseases

New England Journal of Medicine

Volumn 346, Issue 1, 2002, Pages 45-53

  Carrell, Robin W ^a   Lomas, David A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; SERINE PROTEINASE INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR;

ALPHA 1 ANTITRYPSIN DEFICIENCY; BLEEDING; DEMENTIA; EMPHYSEMA; GENE MUTATION; HUMAN; LIVER CIRRHOSIS; PRIORITY JOURNAL; REVIEW; THROMBOSIS; BIOLOGICAL MODEL; CHEMISTRY; DEGENERATIVE DISEASE; GENETICS; METABOLISM; MUTATION; PROTEIN CONFORMATION;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; DEMENTIA; EMPHYSEMA; ENDOPEPTIDASES; HUMANS; LIVER CIRRHOSIS; MODELS, BIOLOGICAL; MUTATION; NEURODEGENERATIVE DISEASES; PROTEASE INHIBITORS; PROTEIN CONFORMATION; SERPINS;

EID: 0037011795     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra010772     Document Type: Review

References (100)

1. The serpin superfamily ofproteinase inhibitors: Structure, function, and regulation
2. 1,-proteinase inhibitor: Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function
3. Structure of a serpin-protease complex shows inhibition by deformation
4. What do dysfunctional serpins tell us about molecular mobility and disease?
5. 1-antitrypsin variant causing hemorrhagic disease
6. 1-antitrypsin Pittsburgh (358 Met→Arg), a fatal bleeding disorder
7. 1-antitrypsin associated with protein C deficiency in a patient with mild bleeding tendency
8. Mechanism of protein C deficiency in a patient with arginine 358 alpha-1-antitrypsin (Pittsburgh mutation): Role in the maintenance of hemostatic balance
9. 2-antiplasmin Enschede: Alanine insertion and abolition of plasmin inhibitory activity
10. 1-antitrypsin for structure and function of serpins
11. Serpin tertiary structure transformation
12. 1-antitrypsin deficiency
13. 1-antitrypsin deficiency
14. Antithrombin mutation database: 2nd (1997) update: For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
15. 436→Thr) results in nonsubstrate-like behavior and in polymerization of the molecule
16. COOH-terminal substitutions in the serpin Cl inhibitor that cause loop overinsertion and subsequent multimerization
17. Cirrhosis associated with alpha-1-antitrypsin deficiency: A previously unrecognized inherited disorder
18. 1-antitrypsin deficiency
19. 1-antitrypsin accumulation in the liver
20. Conformational disease
21. Conformational disease
22. Conformational changes and disease - Serpins, prions and Alzheimer's
23. Aggregates in neurodegenerative disease: Crowds and power?
24. The cerebral proteopathies
25. A phenylalanine 402 to leucine mutation is responsible for a stable inactive conformation of antithrombin
26. Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn→Asp)
27. Antithrombins wibble and wobble (T85M/K): Archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activatioh
28. 1-antitrypsin PiZ
29. 1-antitrypsin variant (Pi-ZZ) associated with plasma deficiency
30. Serum Pi types in some European, American, Asian and African populations
31. 1-antitrypsin
32. Molecular basis of alpha-l-anti-trypsin deficiency
33. 1-antitrypsin deficiency
34. Familial encephalopathy with neuroserpin inclusion bodies
35. Familial dementia caused by polymerization of mutant neuroserpin
36. iiyama (serine 53 (TCC) to phenylalanine 53 (TCC)): A new α1-antitrypsin-deficient variant with mutation on a predicted conserved residue of the serpin backbone
37. Occurrence of alpha-1-antirrypsin deficiency in 155 patients with alcoholic liver disease
38. 53→Phe): Further evidence for intracellular loop-sheet polymerization
39. 52 deleted) forms loop sheet polymers in vivo: Evidence for the C sheet mechanism of polymerization
40. 1-antitrypsin
41. 1-antitrypsin
42. Processing by endoplasmic reticulum mannosidases partitions a secretion-impaired glycoprotein into distinct disposal pathways
43. 1-antitrypsin within the hepatic endoplasmic reticulum does not elevate the steady-state level of grp78/BiP
44. 1-antitrypsin
45. Repair of the secretion defect in the Z form of α1-antitrypsin by addition of a second mutation
46. 1-antitrypsin variant
47. Molecular basis for defective secretion of the Z variant of human alpha-1-proteinase inhibitor: Secretion of variants having altered potential for salt bridge formation between amino acids 290 and 342
48. Hepatic endoplasmic reticulum storage diseases
49. Endoplasmic reticulum storage disease
50. Fibrinogen brescia: Hepatic endoplasmic reticulum storage and hypofibrinogenemia because of a gamma284 Gly→Arg mutation
51. Immunohistochemical investigations of PAS-negative globular intracisternal hyaline in human liver biopsy specimens
52. Ultrastructural liver pathology in patients with minimal liver disease and alpha 1-antitrypsin deficiency: A comparison between heterozygous and homozygous patients
53. Cirrhosis associated with partial deficiency of alpha-1 antitrypsin in an adult
54. 1-antitrypsin deficiency in a 4-year-old girl
55. 1-antitrypsin and liver cirrhosis
56. 1-antitrypsin deficiency
57. 1-antitrypsin deficiency detected by screening of 200,000 infants
58. 1-antitrypsin deficiency
59. 1-antitrypsin deficiency in early childhood
60. 1-antitrypsin deficiency
61. 1-antitrypsin
62. 1-antitrypsin in Puerto Rican children with asthma
63. Atopy, asthma, and emphysema in patients with severe alpha-1-antitrypsin deficiency
64. 1-antitrypsin deficiency: Evaluation of bronchiectasis with CT
65. C-antineutrophil cytoplasmic antibody positivity in vasculitis patients is associated with the Z allele of alpha-1-antitrypsin, and P-antineutrophil cytoplasmic antibody positivity with the S allele
66. 1-antitrypsin deficiency, Pi Z
67. Decline in FEV1 related to smoking status in individuals with severe alpha1-antitrypsin deficiency (PiZZ)
68. 1antitrypsin deficiency, cirrhosis and emphysema
69. 1-antitrypsin
70. 1-antitrypsin augmentation therapy
71. Alphal-antitrypsin deficiency: A position statement of the Canadian thoracic society
72. Translating cell biology into therapeutic advances in Alzheimer's disease
73. Prion protein biology
74. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy
75. Evolution of amyloid: What normal protein folding may tell us about fibrillogenesis and disease
76. Mechanisms of amyloidogenesis
77. Abeta42-positive non-pyramidal neurons around amyloid plaques in Alzheimer's disease
78. Cognitive deficits associated with a recently reported familial neurodegenerative disease: Familial encephalopathy with neuroserpin inclusion bodies
79. Neuroserpin, an axonally secreted serine protease inhibitor
80. Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons: Implications for the regulation of motor learning and neuronal survival
81. Collins bodies and atypical myoclonus bodies: The neuroserpin connection
82. The neuroserpin S52R mutation causes progressive myoclonus epilepsy and a wide distribution of intraneuronal neuroserpin deposits in the CNS
83. Zur klinischen und morphologischen differential-diagnose der progressiven myoklonusepilepsie bei myoklonusköperkrankheit
84. Impairment of the ubiquitin-proteasome system by protein aggregation
85. Metabolic regulation of brain Aβ by neprilysin
86. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways
87. 1-antitrypsin polymers are formed by reactive loop-β-sheet A linkage
88. A 2.6Å structure of a serpin polymer and implications for conformational disease
89. Cleaved antitrypsin polymers at atomic resolution
90. Formation of the antithrombin heterodimer in vivo and the onset of thrombosis
91. ↑-Sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy
92. 1-AT deficiency
93. Reversing neurodegeneration: A promise unfolds
94. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
95. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by molecular chaperone HSP70
96. Genetic suppression of polyglutamine toxicity in Drosophila
97. 1-AT deficiency
98. A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
99. 1-antitrypsin
100. Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1